FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 450 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Rare Identical Twins Born With Different Body Sizes Get Mistaken For... December 13, 2019 A tribute to Professor Gordon McVie February 18, 2021 Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery... August 22, 2023 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 Load more HOT NEWS What Is Peripheral Neuropathy and How Can It Be Prevented or... Cancer in My Community: Reducing Tobacco Use in Tunisia New on NCI’s Websites for December 2020 EMA Recommends Extension of Indications for Tislelizumab
